Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

134.24 +0.04 (+0.03%)
Streaming Delayed Price Updated: 2:03 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
News headline image
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
7 Biotech Stocks to Get In Now Before Investors Catch On ↗
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
News headline image
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗
 
Via Benzinga
News headline image
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Apogee Therapeutics, LLC
Via GlobeNewswire
News headline image
Apogee, Sagimet Debut This Week In First Big IPOs Of Summer ↗
Sagimet and Apogee both made their trading debuts this week, raising cash for their clinical trials after upsizing their respective IPOs. Inflammation and immunology biotech Apogee had the larger of... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.